Efficacy of Daratumumab-Based Regimens Compared to Standard of Care in Transplant-Eligible Multiple Myeloma: A Meta-Analysis

Daratumumab (dara) belongs to a class of monoclonal antibodies that target CD38 receptors expressed on multiple myeloma (MM) cells. It was first approved for MM treatment in 2015. The efficacy and safety of dara have been reported in many studies. In this analysis, we assessed the outcome of dara ad...

Descripción completa

Detalles Bibliográficos
Autores principales: Menon, Trishala, Kataria, Saurabh, Adhikari, Ramesh, Khan, Hira, Khalid, Muhammad Zain, Saeeduddin, Mohammad Omar, Taj, Shafaq, Rehman, Usama, Tekin, Aysun, Singh, Romil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
Internal Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8211300/
https://www.ncbi.nlm.nih.gov/pubmed/34155463
http://dx.doi.org/10.7759/cureus.15098

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8211300/
https://www.ncbi.nlm.nih.gov/pubmed/34155463
http://dx.doi.org/10.7759/cureus.15098

Ejemplares similares